Celgene Grabs VC-Backed Cancer Biotech In $485M Deal
Privately held cancer biotech Quanticel Pharmaceuticals Inc., backed by Versant Ventures, is being acquired by Celgene Corp. for up to $485 million, culminating a more than three-year partnership between the companies,...To view the full article, register now.
Already a subscriber? Click here to view full article